What exactly happens in the hearts of patients with heart failure with preserved ejection fraction (HFpEF)—and how can this ...

Recent data underscores the need for improved primary care detection of heart failure with preserved ejection fraction.

U.S. Launch of MYQORZO® (aficamten) in Late January Met with Strong Demand; Over 275 HCPs Prescribed MYQORZO to an estimated 680 Patients in ...

Can weight loss reverse heart failure? A new study shows that heart muscle cells regain strength and muscle contractions ...

A new Scientific Statement from the Heart Failure Society of America (HFSA) challenges longstanding ambiguity in the ...

Data Trends provide quick, visually memorable data-driven information and insights that are useful in clinical practice.

A new study suggests severe obesity may weaken heart muscle cells in people with heart failure with preserved ejection ...

NVO heads into Q1 with strong GLP-1 drug demand and new Wegovy pill rollout, but pricing pressure, weak guidance and Eli ...

KCCQ (Kansas City Cardiomyopathy Questionnaire): A standardized, patient-reported outcome tool that quantifies symptoms, functional status, and quality of life in heart failure patients.

A new study from Temple University and Cedars-Sinai has revealed that mitochondrial remodeling and metabolic disruptions are key contributors to heart failure with preserved ejection fraction (HFpEF).

Tim is a transformational commercial leader with a proven ability to translate complex science into successful product launches,” said Chris Giordano, President and Chief Executive Officer of Tenax ...

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefit on ...